Century Therapeutics Inc (IPSC)
Century Therapeutics, Inc. is a biotechnology company listed on NASDAQ under the ticker IPSC. The company focuses on developing allogeneic cell therapies for a range of serious diseases, including solid tumors, hematological malignancies, and autoimmune disorders. Its lead candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy designed with Allo-Evasion 5.0 for type 1 diabetes. Century Therapeutics is also advancing CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT therapy with Allo-Evasion 5.0 for B-cell-mediated autoimmune diseases, and CNTY-101, an allogeneic iPSC-derived CAR-iNK therapy with precision gene edits and Allo-Evasion 1.0 intended for CD19-related B-cell autoimmune conditions. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-IPSC
|
$2.15
|
-2.5% Downside
|
Fair
|
$4.75
|
115.4% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-3.7x
|
1.5x
|
—
|
395 M
|
228.7 M
|
10.8%
|
54.2%
|
-0.8
|
—
|
88.6%
|
